SCHEMBL760056

SCHEMBL760056

CC(C)(C)OC(=O)N1Cc2cc(-c3ccc(N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)nn3)ccc2C(c2ccc(F)cc2)C1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
SLC6A2 P23975 5/20 0.39
SLC6A4 P31645 5/20 0.39
SLC6A3 Q01959 5/20 0.39
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
GPR119 Q8TDV5 1/20 0.35
CYP2D6 P10635 1/20 0.35
JAK2 O60674 1/20 0.35
JAK3 P52333 1/20 0.35
PTK2 Q05397 1/20 0.35
DDB1 Q16531 2/20 0.34
CRBN Q96SW2 2/20 0.34
F2RL1 P55085 2/20 0.34
RORC P51449 2/20 0.33
TGFBR1 P36897 1/20 0.33
HPGDS O60760 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3484386 0.83 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL2042744 0.78 SLC6A2 (0.64) SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL12759216 0.78 SLC6A2 (0.64) SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL747351 0.77 KIF11 (0.48) ESR1ESR2SLC6A2SLC6A4SLC6A3
SCHEMBL748535 0.76 SLC6A2 (0.44) ESR1ESR2SLC6A2SLC6A4SLC6A3
SCHEMBL14864833 0.76 SLC6A2 (0.53) ESR1ESR2SLC6A2SLC6A4SLC6A3
SCHEMBL14864331 0.71 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3
SCHEMBL13580255 0.70 NR1H2 (0.39) ESR2SLC6A4GPR119
SCHEMBL22461292 0.68 ESR2 (0.61) ESR1ESR2SLC6A2SLC6A4SLC6A3
SCHEMBL751483 0.67 KIF11 (0.48) ESR1ESR2SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9604960-B2 Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof ALBANY MOLECULAR RESEARCH, INC. (US) 2017-03-28 US disclosed
US-9034899-B2 Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof ALBANY MOLECULAR RESEARCH, INC. (US) 2015-05-19 US disclosed
US-20150126517-A1 ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT 2015-05-07 US disclosed
EP-2429295-B1 ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF ALBANY MOLECULAR RES INC (US) 2013-12-25 EP disclosed
EP-2429295-A1 ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF Albany Molecular Research, Inc. (US) 2012-03-21 EP disclosed
WO-2010132437-A1 ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2010-11-18 WO disclosed
US-20100292242-A1 ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292242-A1 ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF NLN, HTR3B, HTR2C ESR1 3912/4885ESR2 2433/4885SLC6A2 64/4885
US-20150126517-A1 ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF NLN, HTR3B, HTR2C ESR1 3912/4885ESR2 2433/4885SLC6A2 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.